Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Amicus Therapeutics Inc | FOLD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.33 | 04:09:44 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 10.33 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.70 - 14.57 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 10.33 | USD |
Amicus Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.05B | 295.38M | - | 399.36M | -151.58M | -0.51 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Amicus Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FOLD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.07 | 11.07 | 10.32 | 10.57 | 2,507,679 | -0.74 | -6.68% |
| 1 Month | 11.72 | 11.93 | 10.32 | 11.27 | 2,360,623 | -1.39 | -11.86% |
| 3 Months | 12.75 | 14.03 | 10.32 | 12.37 | 3,045,348 | -2.42 | -18.98% |
| 6 Months | 10.66 | 14.57 | 9.70 | 12.19 | 3,009,663 | -0.33 | -3.10% |
| 1 Year | 11.83 | 14.57 | 9.70 | 12.26 | 2,750,532 | -1.50 | -12.68% |
| 3 Years | 9.90 | 14.57 | 5.91 | 10.93 | 2,693,781 | 0.43 | 4.34% |
| 5 Years | 12.62 | 25.39 | 5.91 | 11.60 | 2,731,488 | -2.29 | -18.15% |
Amicus Therapeutics Description
| Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. |
